Please login to the form below
Cubist Pharmaceuticals
This page shows the latest Cubist Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Merck prepares filings for Clostridium antibody
Merck bolstered its anti-infectives pipeline last year with the $8.4bn acquisition of Cubist Pharmaceuticals, which added a range of antibiotics including recently-approved Sivextro (tedizolid phosphate) and Zerbaxa
Latest news
-
Merck hopes for another Keytruda with new immunotherapy deal
Merck also said it expects to see an increase in overall revenue from its recent $8.4bn purchase of Cubist Pharmaceuticals, the maker of blockbuster antibiotic Cubicin, which made $480m.
-
Actavis gets FDA nod for new antibiotic
Avycaz' closest rival among these is Cubist Pharmaceuticals' Zerbaxa (ceftolozane/tazobactam) - which has been tipped as a $1bn-plus product - while the others are Cubist's Sivextro (tedizolid), Durata/Actavis' Dalvance
-
Antibiotics among 7 new drugs backed by EMA
The Medicines Company’s Orbactiv and Cubist’s Sivextro set for European approval. ... Both The Medicines Company's Orbactiv (oritavancin) and Cubist's Sivextro (tedizolid phosphate) were among seven new medicines backed by EMA scientific advisers in
-
FDA backs Cubist's antibiotic Zerbaxa
Combination cephalosporin and beta lactamase inhibitor wins US approval. Cubist Pharmaceuticals has rounded off a busy few months with its second approval for a new antibiotic, this time getting FDA approval ... The drug was filed in Europe for the same
-
Merck stumps up $375m for cancer firm OncoEthix
Follows $8.4bn deal to buy Cubist. Merck &Co has bolstered its cancer pipeline with the acquisition of Swiss biopharma company OncoEthix in a deal valued at up to $375m. ... tumours. The acquisition is Merck's second this month after it agreed an $8.4bn
More from news
Approximately 10 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Curbing the rise of drug resistance
Rekindling anti-microbial innovation . Although doctors and veterinarians (and, indirectly, patients) have a responsibility to cut back the volume of antibiotic prescriptions, it is the pharmaceuticals sector that holds the greatest ... The KPMG report
-
Cubist: Meeting the challenge in antibiotics
Patrick Vink on Cubist Pharmaceuticals’ ambitions in anti-infectives, which have attracted the attention of Merck &Co. ... Cubist expansion. One company that has remained in the field despite these difficulties is US-based Cubist Pharmaceuticals, which
-
Deal Watch table for July 2013
8, 600. Trius Therapeutics / Cubist Pharmaceuticals. Acquisition. Antibiotic pipeline inc TR-701 (tedizolid phosphate, p3). ... 815. Optimer Pharmaceuticals / Cubist Pharmaceuticals. Acquisition. Antibiotic pipeline based on Dificid (fidaxomicin) for
-
Pharma deals during July 2013
Whilst the Elan and Perrigo deal creates a diversified business, several companies, such as Cubist, Ipsen and Spectrum Pharmaceuticals, focused on acquiring assets to bolster their core business areas in antibiotics, ... On the same day, Cubist announced
-
Pharma deals during March 2013
Paying $25m upfront in cash, Cubist Pharmaceuticals is buying the rights to ceftolozane in certain Asia-Pacific and Middle East territories from Astellas. ... Astellas Pharma/ Cubist Pharmaceuticals ††. Acquisition of rights. Ceftolozane for
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Constellation Pharmaceuticals appoints Emma Reeve as CFO
US-based Constellation Pharmaceuticals has appointed Emma Reeve as its chief financial officer to bolster the biopharma’s finance efforts. ... Prior to that he spent ten years at Cubist Pharmaceuticals, Biogen and Covance.
-
Nabriva Therapeutics appoints new chief commercial officer
Prior to serving MSD as its acting vice president, global brand leader anti-infective portfolio, he was vice president, international marketing for the anti-infectives portfolio at Cubist Pharmaceuticals.
-
Caligor Rx appoints Michael Dallmann as director of strategic planning
He brings experience from Cubist Pharmaceuticals and Peninsula Pharmaceuticals. New Jersey-based Caligor Rx has named Michal Dallman to the newly-created role of as director of strategic planning. ... Dallmann - who has over two decades of pharmaceutical
-
Cubist’s Dr Lorianne Masuoka jumps ship to InVivo
Comes amidst MSD’s recent takeover of the antibiotic specialist. InVivo Therapeutics has appointed former Cubist executive team leader Dr Lorianne Masuoka as its new chief medical officer. ... She takes over from the interim CMO, Lou Vaickus. Prior to
-
Cubist picks Robert Perez as its new CEO
He replaces Michael Bonney who will continue as chair. Antibiotic specialist Cubist Pharmaceuticals has announced that CEO Michael Bonney will step down from his position at the end of this year ... Cubist's ambitions have been seen with a number of drug
More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- AZ strengthens Daiichi Sankyo partnership with new ADC deal
- How will the events and exhibitions industry change post-Coronavirus?
- Tecentriq combo fails in advanced triple negative breast cancer
- Bristol-Myers Squibb’s revenues rise on Celgene acquisition
- Aerocrine
- AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML
- FDA approves Sarepta rival NS Pharma’s Duchenne drug
- BMS pledges $300m to tackle health inequity and improve diversity
- Hamell selected by PM Society's 'Creativity for Good' initiative
- Virtual Hackathon on Healthcare Innovation: a Customer Story
- OPEN Health at the World Orphan Drug Conference USA
PMHub
COUCH Health
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...
Latest intelligence
- Virtual Hackathon on Healthcare Innovation: a Customer Story
- How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
- OPEN Health at the World Orphan Drug Conference USA
- Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
- Can involving patients in design transform the clinical trial experience?
- While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...
Quick links
Infographics
